AGAP

Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024

Retrieved on: 
Friday, January 12, 2024
General Health, Finance, Health, Professional Services, Pharmaceutical, AMF, AGAP, Treasury

(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds.

Key Points: 
  • (1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds.
  • In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.
  • The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e.
  • (2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights.

Number of Shares and Voting Rights of Innate Pharma as of October 3, 2023

Retrieved on: 
Monday, October 9, 2023
Pharmaceutical, Professional Services, Health, Finance, Article, Treasury, AMF, AGAP, Holding company, Security (finance)

(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds.

Key Points: 
  • (1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds.
  • In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.
  • The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e.
  • (2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights.

Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023

Retrieved on: 
Friday, July 7, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Treasury, AMF, Article, AGAP, Holding company, Security (finance)

(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds.

Key Points: 
  • (1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds.
  • In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.
  • The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e.
  • (2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights.

Number of Shares and Voting Rights of Innate Pharma as of June 1, 2023

Retrieved on: 
Wednesday, June 7, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Treasury, AMF, Article, AGAP, Holding company, Security (finance)

(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds.

Key Points: 
  • (1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds.
  • In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.
  • The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e.
  • (2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights.

Number of shares and voting rights of Innate Pharma as of May 1, 2023

Retrieved on: 
Tuesday, May 9, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Treasury, AMF, Article, AGAP, Holding company, Security (finance)

(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds.

Key Points: 
  • (1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds.
  • In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.
  • The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e.
  • (2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights.

Number of Shares and Voting Rights of Innate Pharma as of April 1, 2023

Retrieved on: 
Tuesday, April 18, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Treasury, AMF, Article, AGAP, Holding company, Security (finance)

(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds.

Key Points: 
  • (1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds.
  • In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.
  • The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e.
  • (2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights.

Number of Shares and Voting Rights of Innate Pharma as of March 1, 2023

Retrieved on: 
Monday, March 20, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Treasury, AMF, Article, AGAP, Holding company, Security (finance)

The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds.

Key Points: 
  • The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds.
  • In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.
  • The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e.
  • The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights.

Number of Shares and Voting Rights of Innate Pharma as of February 1, 2023

Retrieved on: 
Tuesday, February 21, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, AMF, Article, Treasury, AGAP, Holding company, Security (finance)

(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds.

Key Points: 
  • (1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds.
  • In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.
  • The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e.
  • (2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights.

Number of Shares and Voting Rights of Innate Pharma as of August 1, 2022

Retrieved on: 
Monday, August 8, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Antibody, Article, Cancer, AGAP, Treasury, AMF, Patient, Euronext Paris, Company, Bristol Myers Squibb, Tumor microenvironment, Sanofi, AstraZeneca, Novo Nordisk, Immune system, Vaccine, Fine chemical, Nasdaq, MD

In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.

Key Points: 
  • In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.
  • The total number of theoretical voting rights includes (i) voting rights attached to AGAP 2016, i.e.
  • 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2 and (ii) no voting rights attached to AGAP 2017.
  • (2) The total number of exercisable voting rights (or net voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights.

Number of Shares and Voting Rights of Innate Pharma as of May 1, 2022

Retrieved on: 
Tuesday, May 10, 2022
Pharmaceutical, Health, Oncology, Antibody, AMF, Immune system, Novo Nordisk, Company, Tumor microenvironment, Patient, AGAP, Euronext Paris, Treasury, Cancer, Article, Sanofi, AstraZeneca, Bristol Myers Squibb, Vaccine, Fine chemical, Nasdaq, MD

In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.

Key Points: 
  • In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.
  • The total number of theoretical voting rights includes (i) voting rights attached to AGAP 2016, i.e.
  • 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2 and (ii) no voting rights attached to AGAP 2017.
  • (2) The total number of exercisable voting rights (or net voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights.